Seattle Genetics to Present at the Barclays Global Healthcare Conference 2018
BOTHELL, Wash.--(BUSINESS WIRE)--Mar. 13, 2018--
Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management
will present at the Barclays Global Healthcare Conference 2018 on
Wednesday, March 14, 2018 at 10:45 a.m. Eastern Time. The presentation
will be webcast live and available for replay from Seattle Genetics’
website at www.seattlegenetics.com
in the Investors section.
About Seattle Genetics
Seattle Genetics is an innovative biotechnology company dedicated to
improving the lives of people with cancer through targeted therapies.
The company’s industry-leading antibody-drug conjugate (ADC) technology
harnesses the targeting ability of antibodies to deliver cell-killing
agents directly to cancer cells. Seattle Genetics commercializes
ADCETRIS® (brentuximab vedotin) for the treatment of several types of
CD30-expressing lymphomas. The company is also advancing a robust
pipeline of novel therapies for solid tumors and blood-related cancers
designed to address significant unmet medical needs and improve
treatment outcomes for patients. More information can be found at www.seattlegenetics.com
and follow @SeattleGenetics on Twitter.